Medigen Vaccine Biologics Corporation (6547)

Profile

https://www.medigenvac.com

Medigen Vaccine Biologics Corporation is a biotechnology company specializing in the research, development, and manufacturing of vaccines and biopharmaceuticals. Founded in 2012 and headquartered in Zhubei City, Taiwan, the company is dedicated to addressing global and regional infectious diseases, operating with certified mass-production capabilities for vaccines and biologics. Its portfolio encompasses vaccines in various stages of development, including candidates targeting COVID-19, enterovirus A71, dengue, respiratory syncytial virus (RSV), and influenza. Medigen's work includes advancing both live attenuated and inactivated viral vaccines and developing products adaptable for diverse delivery containers. Positioned within the healthcare sector, the company plays a significant role in regional public health, particularly highlighted by its rapid response during the COVID-19 pandemic. Through international alliances and a focus on affordable biosimilar drugs, Medigen aims to become a central R&D and manufacturing hub in the Asia-Pacific, supporting global efforts to control and prevent infectious diseases.